{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:38:51Z","timestamp":1789015131243,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-022-01371-x","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:02:21Z","timestamp":1644192141000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Effect of N-Acetyl-DL-Leucine on Neurological Symptoms in a Patient with Ataxia-Telangiectasia: a Case Study"],"prefix":"10.1007","volume":"22","author":[{"given":"Maryam","family":"Saberi-Karimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Beyraghi-Tousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoureh","family":"Mirzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gumpricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhosein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"issue":"1","key":"1371_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0543-7","volume":"11","author":"C Rothblum-Oviatt","year":"2016","unstructured":"Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):1\u201321.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1371_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/pr.2016.19","volume":"79","author":"A Nissenkorn","year":"2016","unstructured":"Nissenkorn A, et al. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79(6):889\u201394.","journal-title":"Pediatr Res"},{"key":"1371_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1203\/00006450-198101000-00012","volume":"15","author":"JT Wu","year":"1981","unstructured":"Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res. 1981;15:50\u20132.","journal-title":"Pediatr Res"},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ejpn.2007.04.001","volume":"11","author":"A Stray-Pedersen","year":"2007","unstructured":"Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamsen TG. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol. 2007;11:375\u201380.","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"1371_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/dmcn.13424","volume":"59","author":"NJ van Os","year":"2017","unstructured":"van Os NJ, Haaxma CA, van der Flier M, Merkus PJ, van Deuren M, de Groot IJ, Loeffen J, van de Warrenburg BP, Willemsen MA, A\u2010T Study Group. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;59(7):680\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1371_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/bmb\/ldm012","volume":"81","author":"MF Lavin","year":"2007","unstructured":"Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81(1):129\u201347.","journal-title":"Br Med Bull"},{"key":"1371_CR7","unstructured":"The A-T Society. Ataxia-telangiectasia in children: guidance on diagnosis and clinical care. Rothamsted, UK: The Ataxia-Telangiectasia Society, 2014. Available at: http:\/\/www.atsociety.org.uk\/data\/files\/Wil liam\/A T_Clinical_Guidance_Document_Final.pdf (accessed 1 Oct 2016)."},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000148206","volume":"14","author":"C Ferber-Viart","year":"2009","unstructured":"Ferber-Viart C, Dubreuil C, Vidal PP. Effects of acetyl-DLleucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy. Audiol neuro-otol. 2009;14:17\u201325.","journal-title":"Audiol neuro-otol"},{"issue":"10","key":"1371_CR9","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"M Strupp","year":"2013","unstructured":"Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol. 2013;260(10):2556\u201361.","journal-title":"J Neurol"},{"key":"1371_CR10","unstructured":"Laumen A, Schneider S, Bremova-Ertl T, Kraus L, Feil K, Strupp M. Rates of responsiveness of acetyl-DL-leucine treatment for ataxia symptoms. Eur J Neurol. 2019;26."},{"key":"1371_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40673-016-0046-2","volume":"3","author":"R Schniepp","year":"2016","unstructured":"Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, et al. Acetyl- DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum Ataxias. 2016;3:8.","journal-title":"Cerebellum Ataxias"},{"key":"1371_CR12","doi-asserted-by":"publisher","unstructured":"Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, Davis W, Evans W, Flint S, Galione A, Granzer U. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia. Trials. 2021;22(1):1\u20135.https:\/\/doi.org\/10.1186\/s13063-020-05009-3.","DOI":"10.1186\/s13063-020-05009-3"},{"key":"1371_CR13","unstructured":"Mohamadian H, Akbari H, Gilasi H, Gharlipour Z, Moazami A, Aghajani M. Validation of pediatric quality of life questionnaire (PedsQL) in Kashan city, (in Persian). J Ilam Univ Med Sci.;22(3):10\u201318."},{"key":"1371_CR14","doi-asserted-by":"crossref","unstructured":"Varni, J. W., Burwinkle, T. M., Seid, M., & Skarr, D. (2003). The PedsQL\u2122* 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambulatory pediatrics, 3(6), 329\u2013341.","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2"},{"issue":"5","key":"1371_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00228-018-02617-6","volume":"75","author":"P Vanderkam","year":"2019","unstructured":"Vanderkam P, Blanchard C, Naudet F, Pouchain D, Roussel HV, Perault-Pochat MC, Jaafari N, Boussageon R. Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials. Eur J Clin Pharmacol. 2019;75(5):603\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1371_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-016-0786-x","volume":"17","author":"K Feil","year":"2017","unstructured":"Feil K, Adrion C, Teufel J, B\u00f6sch S, Claassen J, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurol. 2017;17(1):1\u20131.","journal-title":"BMC Neurol"},{"key":"1371_CR17","doi-asserted-by":"crossref","unstructured":"Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Sch\u00f6ls L. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial. JAMA network open. 2021 Dec 1;4(12):e2135841.","DOI":"10.1001\/jamanetworkopen.2021.35841"},{"key":"1371_CR18","first-page":"088307382110283","volume":"7","author":"A Brueggemann","year":"2021","unstructured":"Brueggemann A, Bicvic A, Goeldlin M, Kalla R, Kerkeni H, Mantokoudis G, Abegg M, Koln\u00edkov\u00e1 M, Mohaupt M, Bremova-Ertl T. Effects of acetyl-DL-leucine on ataxia and downbeat-nystagmus in six patients with ataxia telangiectasia. J Child Neurol. 2021;7:08830738211028394.","journal-title":"J Child Neurol"},{"key":"1371_CR19","doi-asserted-by":"crossref","unstructured":"Churchill GC, Strupp M, Galione A, Platt FM. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. PloS one. 2020 Feb 27;15(2):e0229585.","DOI":"10.1371\/journal.pone.0229585"},{"key":"1371_CR20","first-page":"1","volume":"13","author":"T Bremova-Ertl","year":"2021","unstructured":"Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K. Efficacy and safety of N-acetyl-l-leucine in Niemann-Pick disease type C. J Neurol. 2021;13:1\u20132.","journal-title":"J Neurol"},{"issue":"5","key":"1371_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00415-015-7734-3","volume":"262","author":"JO Pelz","year":"2015","unstructured":"Pelz JO, Fricke C, Saur D, Classen J. Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series. J Neurol. 2015;262(5):1373\u20135.","journal-title":"J Neurol"},{"key":"1371_CR22","doi-asserted-by":"crossref","unstructured":"Vibert N, Vidal PP. In vitro effects of acetyl\u2010dl\u2010leucine (tanganil\u00ae) on central vestibular neurons and vestibulo\u2010ocular networks of the guinea\u2010pig. European Journal of Neuroscience. 2001 Feb;13(4):735\u201348.","DOI":"10.1046\/j.0953-816x.2000.01447.x"},{"key":"1371_CR23","unstructured":"Neuzil E, Ravaine S, Cousse H. La N-ace \u00b4tyl-DL-leucine, me \u00b4dicament symptomatique de vertigineux. Bull Soc Pharm Bordx. Bull Soc Pharm Bordx. 2002; 141: 15\u201338"},{"key":"1371_CR24","doi-asserted-by":"crossref","unstructured":"Churchill GC, Strupp M, Galione A, Platt FM. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. PLoS one. 2020 Feb 27;15(2):e0229585.","DOI":"10.1371\/journal.pone.0229585"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-022-01371-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-022-01371-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-022-01371-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:25:55Z","timestamp":1674807955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-022-01371-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s12311-022-01371-x","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"20 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been approved in Ethics Committee of Mashhad University of Medical Sciences (ID: IR.MUMS.REC.1400.176), Mashhad, Iran.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}